Werewolf Therapeutics GAAP EPS of $0.08 beats by $0.40, revenue of $21M
Howl's performance significantly exceeded market expectations. GAAP EPS was $0.08, which was $0.40 higher than anticipated, and revenue reached $21M.
We noted the strong earnings surprise confirmed through the earnings announcement and the recent upward trend. From July 24 to July 30, the stock consistently rose from its lows, creating higher highs, and particularly on July 30, it touched a high of $0.54, demonstrating strong momentum, which serves as the rationale for entry.
If the stock price maintains the short-term support level of $0.45, I will take profits at the resistance level of $0.55. If the support level of $0.45 breaks, I will cut losses.
The decision to enter based on the earnings announcement and the rising momentum of the theme was appropriate; however, the response to the subsequent sharp decline immediately after entry was inadequate. The stock price rose to $0.50, approaching the target price, but the low on the entry date of July 31 fell to $0.34, dropping below the stop-loss level of $0.45. As a result, the predicted return was +2.5%, but the actual outcome was -12.5%, marking a failed trade that did not adhere to the stop-loss line.
Even if positive earnings news occurs, if the volatility on the day of entry is greater than expected, it will be important to monitor the rapid price deviations more sensitively rather than relying solely on support level figures. In particular, considering the volatility immediately following news announcements, I will apply stricter stop-loss criteria or consider a strategy of entering positions in increments.